Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06286800 · ClinicalTrials.gov registry record · NA
Personalized Transcranial Direct Current Stimulation in Stroke Recovery
A NA study of Stroke and Ischemic Stroke, sponsored by The Methodist Hospital Research Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06286800: Recruiting NA study of Stroke and Ischemic Stroke, sponsored by The Methodist Hospital Research Institute.
NCT06286800 is a NA study of Stroke and Ischemic Stroke that is actively recruiting participants, run by The Methodist Hospital Research Institute. The registered enrollment target is 80 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06286800, a NA study of Stroke and Ischemic Stroke, is actively recruiting participants, sponsored by The Methodist Hospital Research Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The central objective of this application is to explore the neural substrate of personalized tDCS (ptDCS) and to determine whether the paradigm for each stroke patient can predict the amount of sustained clinical improvement through increased connectivity as measured by a biomarker of plasticity.
Primary Outcome
Task activation, resting state functional connectivity
Conditions Studied
Interventions
- DEVICE Transcranial direct current stimulation (tDCS) with OT
- DEVICE Sham tDCS with OT
Study Locations (1)
Texas
- Houston Methodist Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-12-18 |
| Est. Completion | 2027-09-14 |
| Phase | NA |
What NCT06286800 shows while recruiting
NCT06286800 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which Transcranial direct current stimulation (tDCS) with OT is the first listed.
NCT06286800 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06286800 about?
NCT06286800 is a clinical study titled "Personalized Transcranial Direct Current Stimulation in Stroke Recovery". The central objective of this application is to explore the neural substrate of personalized tDCS (ptDCS) and to determine whether the paradigm for each stroke patient can predict the amount of sustained clinical improvement through increased connectivity as measured by a biomarker of plasticity.
What is the current status of trial NCT06286800?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2024-12-18. Estimated completion is 2027-09-14.
What conditions does trial NCT06286800 study?
This clinical trial studies the following conditions: Stroke, Ischemic Stroke, Chronic Stroke, Hemorrhage Brain.
What interventions are being tested in trial NCT06286800?
The interventions under investigation include: Transcranial direct current stimulation (tDCS) with OT (DEVICE), Sham tDCS with OT (DEVICE).
Who is sponsoring clinical trial NCT06286800?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06286800 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06286800's enrollment target sits among peer trials
80 167th of 454 higher than 282 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
-
Safety and Feasibility of an ExoNET for Supination Assistance for Stroke Survivors
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI